Dwarfism Clinical Trial
Official title:
A Phase 2 Study Extension Period of Pegylated Somatropin (PEG-somatropin) in the Treatment of Children With Idiopathic Short Stature: An Open, Non-controlled Observational Study.
After the first stage (52 weeks) of Phase II clinical trial, Pegylated recombinant human growth hormone (PEG-rhGH) injection of appropriate dose in compliance with ISS clinical treatment strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable medication guidance information for clinical diagnosis and treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
| Completed |
NCT00001190 -
Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
|
Phase 2 | |
| Recruiting |
NCT03535415 -
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
|
Phase 3 | |
| Recruiting |
NCT03221088 -
A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature
|
Phase 2 | |
| Completed |
NCT00234533 -
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
|
Phase 3 | |
| Completed |
NCT00001754 -
Study of Skeletal Disorders and Short Stature
|
N/A | |
| Recruiting |
NCT03635580 -
Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS
|
Phase 3 | |
| Completed |
NCT00001343 -
The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome
|
Phase 2 | |
| Completed |
NCT00001536 -
Issues Surrounding Prenatal Genetic Testing for Achondroplasia
|
N/A |